The pharmaceutical giant plans to continue offering 23andMe’s DNA testing service and pledged to adopt its privacy practices ...

Novel oral agent nerandomilast slowed lung capacity decline in patients with non-idiopathic pulmonary fibrosis (IPF) ...

The British Society for Rheumatology has moved toward a life course approach when updating guidelines for several rheumatic ...

Not unlike Regeneron's acquisition of 23andMe, Predictive Oncology's AI-driven breakthroughs reflect a broader transformation ...

Depemokimab reduces exacerbations regardless of baseline asthma control, suggesting uncontrolled symptoms are not necessary ...

The NIFTY MIDCAP 150's movements reflect ongoing market dynamics, with Global Health, JSW Infra, and GlaxoSmithKline ...

Nifty Pharma stocks, including GSK, Jubilant Pharmova, Eris Life, Gland Pharma and Torrent Pharma, saw gains up to 8% as ...

Stocks from pharmaceutical companies and healthcare spaces dominated analysts' choices for Thursday's trading session.

ICICI Securities recommended reduce rating on GlaxoSmithKline Pharmaceuticals with a target price of Rs 2,600 in its research ...

Migraine is recognized globally as the seventh most disabling condition across all diseases, accounting for approximately 2.9% of all years lived with disability (YLDs). It is also the top cause of ...

The company is working closely with the contract manufacturing facility for resumption of operations. Shares of ...

Current treatment paradigms for lupus nephritis offer significant room for improvement, according to a presenter at the ...